A comprehensive functional analysis of TP53 mutations in human leukemia may refute a working hypothesis - primarily based on mouse studies - that missense mutations confer new cancer-causing functions to the p53 tumor suppressor protein; the new study instead suggests that these mutations exert a "dominant-negative" effect that reduces the cancer-suppressing activity of wild-type p53, the authors say.
The TP53 gene was discovered 40 years ago and it now known to be the most frequently mutated gene in human cancer. Initially, TP53 was mischaracterized as an oncogene but human genetic studies ultimately established that it encodes a tumor suppressor. But how cancer-associated mutations in TP53 alter the function of wild-type p53 has continued to be the subject of debate.
The vast majority of TP53 mutations across all cancer types are missense mutations, which can result in non-functional or dysfunctional p53. Based largely on mouse model experiments, it has been hypothesized that certain missense mutations can transform the p53 tumor suppressor into a tumor promoter via so-called oncogenic "gain of function" (GOF) effects.
To explore the functional consequences of p53 mutations, researchers performed a comprehensive analysis of TP53 mutations in human myeloid leukemia. Using CRISPR/Cas9 gene editing technology, the authors generated isogenic human leukemia cell lines featuring the most common p53 missense variants.
This isogenic analysis - as well as comprehensive mutational screening, in vivo experiments in mice and an analysis of clinical data - did not support the notion that missense mutations confer new oncogenic functions to the p53 tumor suppressor protein.
Instead, the authors discovered that the mutations confer either loss of function effects or dominant-negative effects (DNE) that reduce the tumor-supressing efficacy of wild-type p53 in human leukemia. In mice, the DNE of p53 missense variants confers a selective advantage to hematopoietic cells on DNA damage. Analysis of clinical outcomes in patients with acute myeloid leukemia showed no evidence of GOF for TP53missense mutations. Thus, a DNE is the primary unit of selection for TP53 missense mutations in myeloid malignancies.
https://science.sciencemag.org/content/365/6453/599
Type of TP53 mutations and their affect in cancer
- 2,596 views
- Added
Edited
Latest News
Ancient viral DNA in the hu…
By newseditor
Posted 26 May
AI to analyze clumping prot…
By newseditor
Posted 26 May
Reversible, non-hormonal ma…
By newseditor
Posted 26 May
Dissection of the schizophr…
By newseditor
Posted 26 May
Protease action on controll…
By newseditor
Posted 25 May
Other Top Stories
Probing neuronal membrane potentials and ionic fluxes at the single…
Read more
Sewing high-tech heating patches to clothes to keep you warm
Read more
PET scan to detect changes in gene expression of epigenetic enzymes…
Read more
Artificial Intelligence to detect infectious bacterial on the skin
Read more
Artificial intelligence system learns to diagnose, classify intracr…
Read more
Protocols
SEMORE: SEgmentation and MO…
By newseditor
Posted 26 May
Spatially resolved lipidomi…
By newseditor
Posted 24 May
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Publications
Integrating human endogenou…
By newseditor
Posted 26 May
The thalamic reticular nucl…
By newseditor
Posted 26 May
PMI-controlled mannose meta…
By newseditor
Posted 26 May
Protein-membrane interactio…
By newseditor
Posted 26 May
Toward an interventional sc…
By newseditor
Posted 26 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar